Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case
Hydroxycarbamide is used in the treatment of essential thrombocytosis and other myeloproliferative disorders. We report the case of a 63-year-old woman with essential thrombocytosis who had melanonychia after the long-term use of the hydroxycarbamide with a dose of 1000 mg/day. Two years after the i...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2015/653178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553580942327808 |
|---|---|
| author | Umit Yavuz Malkan Gursel Gunes Eylem Eliacik Okan Yayar Ibrahim Celalettin Haznedaroglu |
| author_facet | Umit Yavuz Malkan Gursel Gunes Eylem Eliacik Okan Yayar Ibrahim Celalettin Haznedaroglu |
| author_sort | Umit Yavuz Malkan |
| collection | DOAJ |
| description | Hydroxycarbamide is used in the treatment of essential thrombocytosis and other myeloproliferative disorders. We report the case of a 63-year-old woman with essential thrombocytosis who had melanonychia after the long-term use of the hydroxycarbamide with a dose of 1000 mg/day. Two years after the initiation of the hydroxycarbamide, our patient had pain on her toes and melanonychia on her nails. Hydroxycarbamide treatment was discontinued because of pain and she was given anagrelide treatment. The pathogenesis of melanonychia secondary to long-term hydroxycarbamide treatment is not yet well understood. Some investigators suggested that genetic factors, induction of melanocytes, and some changes in nail matrix could be the reason of hydroxycarbamide related melanonychia. Our patient has suffered color changes in her nails as well as pain that made us doubtful for a beginning of ulceration besides melanonychia. Maybe early clinical reaction of discontinuation of the drug has prevented more severe side effect like ulceration in our patient. Also side effect of hydroxycarbamide has developed more slowly in our patient compared to other patients in the mentioned study. To conclude, long-term hydroxycarbamide treatment can cause mucocutaneous side effects and more studies should be done in future in order to reveal the underlying mechanism. |
| format | Article |
| id | doaj-art-f29455492e0a40d39aa0eec2b96b1e3d |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-f29455492e0a40d39aa0eec2b96b1e3d2025-02-03T05:53:41ZengWileyCase Reports in Hematology2090-65602090-65792015-01-01201510.1155/2015/653178653178Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis CaseUmit Yavuz Malkan0Gursel Gunes1Eylem Eliacik2Okan Yayar3Ibrahim Celalettin Haznedaroglu4Department of Hematology, School of Medicine, Hacettepe University, 0100 Ankara, TurkeyDepartment of Hematology, School of Medicine, Hacettepe University, 0100 Ankara, TurkeyDepartment of Hematology, School of Medicine, Hacettepe University, 0100 Ankara, TurkeyDepartment of Hematology, School of Medicine, Hacettepe University, 0100 Ankara, TurkeyDepartment of Hematology, School of Medicine, Hacettepe University, 0100 Ankara, TurkeyHydroxycarbamide is used in the treatment of essential thrombocytosis and other myeloproliferative disorders. We report the case of a 63-year-old woman with essential thrombocytosis who had melanonychia after the long-term use of the hydroxycarbamide with a dose of 1000 mg/day. Two years after the initiation of the hydroxycarbamide, our patient had pain on her toes and melanonychia on her nails. Hydroxycarbamide treatment was discontinued because of pain and she was given anagrelide treatment. The pathogenesis of melanonychia secondary to long-term hydroxycarbamide treatment is not yet well understood. Some investigators suggested that genetic factors, induction of melanocytes, and some changes in nail matrix could be the reason of hydroxycarbamide related melanonychia. Our patient has suffered color changes in her nails as well as pain that made us doubtful for a beginning of ulceration besides melanonychia. Maybe early clinical reaction of discontinuation of the drug has prevented more severe side effect like ulceration in our patient. Also side effect of hydroxycarbamide has developed more slowly in our patient compared to other patients in the mentioned study. To conclude, long-term hydroxycarbamide treatment can cause mucocutaneous side effects and more studies should be done in future in order to reveal the underlying mechanism.http://dx.doi.org/10.1155/2015/653178 |
| spellingShingle | Umit Yavuz Malkan Gursel Gunes Eylem Eliacik Okan Yayar Ibrahim Celalettin Haznedaroglu Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case Case Reports in Hematology |
| title | Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case |
| title_full | Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case |
| title_fullStr | Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case |
| title_full_unstemmed | Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case |
| title_short | Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case |
| title_sort | melanonychia secondary to long term treatment with hydroxycarbamide an essential thrombocytosis case |
| url | http://dx.doi.org/10.1155/2015/653178 |
| work_keys_str_mv | AT umityavuzmalkan melanonychiasecondarytolongtermtreatmentwithhydroxycarbamideanessentialthrombocytosiscase AT gurselgunes melanonychiasecondarytolongtermtreatmentwithhydroxycarbamideanessentialthrombocytosiscase AT eylemeliacik melanonychiasecondarytolongtermtreatmentwithhydroxycarbamideanessentialthrombocytosiscase AT okanyayar melanonychiasecondarytolongtermtreatmentwithhydroxycarbamideanessentialthrombocytosiscase AT ibrahimcelalettinhaznedaroglu melanonychiasecondarytolongtermtreatmentwithhydroxycarbamideanessentialthrombocytosiscase |